ストックスクリーナーアプリを入手
0.7361
0.78%
-0.0058
前日終値:
$0.7419
開ける：
$0.77
24時間の取引高:
251.40K
Relative Volume:
0.48
時価総額：
$66.66M
収益：
$5.12M
当期純損益:
$-67.00M
株価収益率:
-0.5007
EPS:
-1.47
ネットキャッシュフロー:
$-38.94M
1週間 パフォーマンス:
-0.10%
1か月 パフォーマンス:
+3.38%
6か月 パフォーマンス:
-74.70%
1年 パフォーマンス:
-85.25%
1日の値動き範囲:
$0.7096
$0.779
1週間の範囲:
$0.6892
$0.7799
52週間の値動き範囲:
$0.6109
$11.41
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
名前
Verrica Pharmaceuticals Inc
セクター
電話
484-453-3300
住所
10 NORTH HIGH STREET, WEST CHESTER, PA
VRCA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
0.7361 | 66.66M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | アップグレード | Needham | Hold → Buy |
| 2023-03-22 | 開始されました | Jefferies | Buy |
| 2023-02-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-12-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-06-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-24 | 開始されました | Northland Capital | Outperform |
| 2020-03-24 | 開始されました | Needham | Buy |
| 2019-02-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Verrica Pharmaceuticals Inc (VRCA) 最新ニュース
Verrica Pharmaceuticals secures covenant waiver - Investing.com India
Common Warts Market to Expand Significantly by 2034, States - openPR
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Verrica reports high response rate in skin cancer study - MSN
Molluscum Contagiosum Market Expected to rise, 2034 | Verrica Pharmaceuticals, Novan and Ligand Pharmaceuticals, Veloce Biopharma, expected to drive market - Barchart
Barclays PLC Grows Stake in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Shareholders Can't Ignore US$1.1m Of Sales By Verrica Pharmaceuticals Insiders - Simply Wall St
Verrica Showcases Promising VP-315 Data at Dermatology Conference - MyChesCo
Verrica Pharmaceuticals Announces Presentation of Three - GlobeNewswire
Verrica reports high response rate in skin cancer study By Investing.com - Investing.com Canada
Verrica's Skin Cancer Drug Shows 97% Response Rate in Phase 2 Trial, Complete Clearance in Half of Tumors - StockTitan
Certain Pre-Funded Warrants of Verrica Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2025. - Marketscreener.com
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Shares Bought by Jane Street Group LLC - Defense World
Barclays PLC Grows Position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Jefferies cuts Verrica stock target to $3, maintains Buy rating - Investing.com
Immedica Pharma to Acquire Marinus Pharmaceuticals in $151 Million Deal - MyChesCo
State Street Corp Buys 61,041 Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
60,000 Shares in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Purchased by Sanctuary Advisors LLC - Defense World
Verrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline Development - MSN
Needham & Company LLC Reiterates Hold Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals Grants Stock Option to New COO David Zawitz - MSN
Verrica reports rise in YCANTH applicator units in Q4 By Investing.com - Investing.com South Africa
Verrica reports rise in YCANTH applicator units in Q4 - Investing.com
Verrica Provides Business and Operational Update - GlobeNewswire
Verrica Pharma's YCANTH Sales Surge in Q4; Plans Game-Changing Single Applicator Launch for 2025 - StockTitan
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031:Verrica Pharmaceuticals,AbbVie Inc,Glenmark - EIN News
Verition Fund Management LLC Acquires New Holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Position Reduced by Fmr LLC - Defense World
Verrica Pharmaceuticals stock hits 52-week low at $0.7 By Investing.com - Investing.com Canada
Verrica Pharmaceuticals stock hits 52-week low at $0.7 - Investing.com
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Drops By 32.6% - Defense World
Verrica Pharmaceuticals' SWOT analysis: stock faces headwinds amid strategic shift - Investing.com
Verrica Pharmaceuticals' SWOT analysis: stock faces headwinds amid strategic shift By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Inc. Appoints David Zawitz as Chief Operating Officer - Marketscreener.com
GLP-1 Receptor Agonist Market Is Booming Worldwide 2024-2031: Novan Inc., Verrica Pharmaceuticals, AbbVie - EIN News
Verrica Pharmaceuticals appoints new COO By Investing.com - Investing.com Australia
PERCEPTIVE ADVISORS LLC Increases Stake in Verrica Pharmaceutica - GuruFocus.com
Verrica Pharmaceuticals appoints new COO - Investing.com India
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verrica Pharmaceuticals Appoints New Chief Operating Officer - TipRanks
Verrica Pharmaceuticals Inc (VRCA) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):